OBJECTIVES: (1) Develop a methodology for obtaining reliable cognitive and developmental data in children with neurodegenerative disease and cognitive impairment and in turn monitor disease state and treatment outcomes. (2) Demonstrate validity of age-equivalent scores. METHODS: We present guidelines for obtaining accurate test scores in low-functioning and behaviorally disruptive pediatric patients, followed by a method validation study: (1) using disease-specific protocols to assess salient aspects of the known phenotype, (2) selecting appropriate tests, (3) managing behavior, and (4) using age-equivalent scores on standardized tools. We used the Bayley Scales of Infant Development-III or Kaufman Assessment Battery for Children-II with a group of 25 children with mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo syndrome type A) with dementia. To demonstrate concurrent validity, we used the Vineland Adaptive Behavior Scales-II, comparing parent-reported age-equivalent scores (AEs) with those of the cognitive measures. RESULTS: We were successful in obtaining cognitive age-equivalents for 25 patients with MPS IIIA including those with severe behavioral disruption and a correlation of 0.95 was obtained comparing scores on the parent measure with cognitive age-equivalents validating the age-equivalent approach. CONCLUSION: An approach to the assessment of severely impaired children including those with behavioral disruption was implemented and is applicable to children with other severe neurological diseases. This approach will enhance the assessment of disease progression and monitoring of treatment outcome in clinical trials.
OBJECTIVES: (1) Develop a methodology for obtaining reliable cognitive and developmental data in children with neurodegenerative disease and cognitive impairment and in turn monitor disease state and treatment outcomes. (2) Demonstrate validity of age-equivalent scores. METHODS: We present guidelines for obtaining accurate test scores in low-functioning and behaviorally disruptive pediatric patients, followed by a method validation study: (1) using disease-specific protocols to assess salient aspects of the known phenotype, (2) selecting appropriate tests, (3) managing behavior, and (4) using age-equivalent scores on standardized tools. We used the Bayley Scales of Infant Development-III or Kaufman Assessment Battery for Children-II with a group of 25 children with mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo syndrome type A) with dementia. To demonstrate concurrent validity, we used the Vineland Adaptive Behavior Scales-II, comparing parent-reported age-equivalent scores (AEs) with those of the cognitive measures. RESULTS: We were successful in obtaining cognitive age-equivalents for 25 patients with MPS IIIA including those with severe behavioral disruption and a correlation of 0.95 was obtained comparing scores on the parent measure with cognitive age-equivalents validating the age-equivalent approach. CONCLUSION: An approach to the assessment of severely impaired children including those with behavioral disruption was implemented and is applicable to children with other severe neurological diseases. This approach will enhance the assessment of disease progression and monitoring of treatment outcome in clinical trials.
Authors: F Baehner; C Schmiedeskamp; F Krummenauer; E Miebach; M Bajbouj; C Whybra; A Kohlschütter; C Kampmann; M Beck Journal: J Inherit Metab Dis Date: 2005 Impact factor: 4.982
Authors: F R Volkmar; S S Sparrow; D Goudreau; D V Cicchetti; R Paul; D J Cohen Journal: J Am Acad Child Adolesc Psychiatry Date: 1987-03 Impact factor: 8.829
Authors: B J Poorthuis; R A Wevers; W J Kleijer; J E Groener; J G de Jong; S van Weely; K E Niezen-Koning; O P van Diggelen Journal: Hum Genet Date: 1999 Jul-Aug Impact factor: 4.132
Authors: Holly R Martin; Michele D Poe; Debra Reinhartsen; Rebecca E Pretzel; Jackson Roush; Angela Rosenberg; Stacey C Dusing; Maria L Escolar Journal: Acta Paediatr Date: 2008-04 Impact factor: 2.299
Authors: J Edmond Wraith; Michael Beck; Roderick Lane; Ans van der Ploeg; Elsa Shapiro; Yong Xue; Emil D Kakkis; Nathalie Guffon Journal: Pediatrics Date: 2007-06-04 Impact factor: 7.124
Authors: Elsa G Shapiro; Igor Nestrasil; Kathleen A Delaney; Kyle Rudser; Victor Kovac; Nitin Nair; Charles W Richard; Patrick Haslett; Chester B Whitley Journal: J Pediatr Date: 2016-01-16 Impact factor: 4.406
Authors: Elizabeth Richardson; Jessica Burnell; Heather R Adams; Richard W Bohannon; Elizabeth Nicole Bush; Michelle Campbell; Wen Hung Chen; Stephen Joel Coons; Elektra Papadopoulos; Bryce R Reeve; Daniel Rooks; Gregory Daniel Journal: Ther Innov Regul Sci Date: 2018-05-08 Impact factor: 1.778
Authors: Elsa G Shapiro; Igor Nestrasil; Alia Ahmed; Andrew Wey; Kyle R Rudser; Kathleen A Delaney; Robin K Rumsey; Patrick A J Haslett; Chester B Whitley; Michael Potegal Journal: Mol Genet Metab Date: 2015-03-05 Impact factor: 4.797
Authors: An N Dang Do; Audrey E Thurm; Cristan A Farmer; Ariane G Soldatos; Colby E Chlebowski; Julie K O'Reilly; Forbes D Porter Journal: Am J Med Genet A Date: 2021-12-16 Impact factor: 2.578
Authors: Elsa Shapiro; Jessica Bernstein; Heather R Adams; Ann J Barbier; Teresa Buracchio; Peter Como; Kathleen A Delaney; Florian Eichler; Jonathan C Goldsmith; Melissa Hogan; Sarrit Kovacs; Jonathan W Mink; Joanne Odenkirchen; Melissa A Parisi; Alison Skrinar; Susan E Waisbren; Andrew E Mulberg Journal: Mol Genet Metab Date: 2016-04-14 Impact factor: 4.797
Authors: Anne C Wheeler; Angela Gwaltney; Melissa Raspa; Katherine C Okoniewski; Elizabeth Berry-Kravis; Kelly N Botteron; Dejan Budimirovic; Heather Cody Hazlett; David Hessl; Molly Losh; Gary E Martin; Susan M Rivera; Jane E Roberts; Donald B Bailey Journal: Pediatrics Date: 2021-05 Impact factor: 7.124
Authors: Arunabha Ghosh; Elsa Shapiro; Stewart Rust; Kathleen Delaney; Samantha Parker; Adam J Shaywitz; Adelaida Morte; Gillian Bubb; Maureen Cleary; Tien Bo; Christine Lavery; Brian W Bigger; Simon A Jones Journal: Orphanet J Rare Dis Date: 2017-06-26 Impact factor: 4.123